Sanner GmbH, a global leader in desiccant solutions and packaging for the pharmaceutical and healthcare industries, is set to showcase significant advancements in its portfolio at Pharmapack Paris 2025, in January. The company will highlight innovations in desiccant and effervescent tablet packaging, alongside its expanding Contract Development and Manufacturing Organisation (CDMO) services, underscoring its commitment to meeting the evolving needs of the global healthcare market.
Driving Innovation for Efficiency and Sustainability
Sanner‘s dedication to innovation is evident in its efforts to enhance packaging solutions. At the forefront is the optimisation of the child-resistant TabTec® CR packaging, which now features improved tightness and moisture protection, crucial for safeguarding sensitive active ingredients. This improvement is part of Sanner’s Advance with Agility™ programme, designed to accelerate product launches, achieve stability targets using predictive modelling, and ensure market-readiness.
In line with growing demand for eco-friendly packaging solutions, Sanner continues to prioritise sustainability. The company is expanding its range of sustainable effervescent tablet packaging, including the bio-based Sanner BioBase®. Moreover, in response to the European Packaging & Packaging Waste Regulation (PPWR), which mandates that all packaging must be recyclable by 2030, Sanner is advancing new packaging solutions incorporating post-consumer recycled (PCR) materials. These efforts reinforce Sanner’s commitment to reducing its environmental footprint while supporting industry-wide sustainability goals.
Expanding CDMO Capabilities for Global Growth
Sanner is accelerating its transformation into a leading global MedTech CDMO. The company’s recent acquisitions of Springboard and Gilero enhance its ability to offer comprehensive services across the medical device development lifecycle. With this expanded capacity, Sanner is now better equipped to produce clinical batches, pilot runs, and commercial volumes, positioning itself as a key partner for medical device manufacturers worldwide.
Sanner is also significantly growing its global manufacturing capabilities. In 2025, the company will open a state-of-the-art flagship facility in Bensheim, Germany, which will include a 100,000 square metre production area and a 300 square metre technology and innovation centre. Set to be fully operational by early 2025, this new facility will support Sanner’s expanding CDMO services and further strengthen its competitive position in the MedTech space.
Global Footprint: Expanding Manufacturing Capabilities in China and the U.S.
Sanner continues to expand its global presence with the recent opening of a new plant in Kunshan, China. The company is also set to launch a production facility in Greensboro, USA, in the second quarter of 2025, focused on injection moulding and desiccant filling. These strategic investments align with Sanner’s global growth strategy, ensuring it can meet the increasing demand for high-quality, scalable solutions in the pharmaceutical and healthcare sectors.
As Christian Classen, CSO of Sanner, explains, “We are excited to showcase how we are executing our strategy to reinforce our leadership in desiccant solutions and expand our global CDMO services. These developments will enable us to better serve the healthcare industry, ensuring our customers have access to high-quality, innovative solutions.”
With its ongoing investments in technology, sustainability, and global manufacturing capacity, Sanner is poised to continue driving growth and innovation across the pharmaceutical and medical device industries, further solidifying its position as an industry leader.